Ublituximab, an Optimized Anti-CD20 Monoclonal Antibody, Demonstrates Greater NK-Mediated ADCC Than Rituximab in Waldenstrom’s Macroglobulinemia Patients Supporting a Therapeutic Strategy with Ublituximab.

Drug Category : Array
Conference Category : Array
Lead Author : Le Garff-Tavernier M, Leblond V, et al.
Published Date : 11/12/2012
Download Link : https://www.tgtherapeutics.com/wp-content/uploads/2019/03/ASH2012Poster1654.pdf
Download Text : Download
Popup Confirmation? :
site-sidebar-layout : default
ast-site-content-layout : default
site-content-style : default
site-sidebar-style : default
theme-transparent-header-meta : default
stick-header-meta : default
astra-migrate-meta-layouts : set
Scroll to Top